RxDoctor Payments Data

Valerie Scott

Nurse Practitioner · Shreveport, LANPI 1710969795

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Amgen at 33.1% of the total. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,780in general payments, 2019–2025

Across 479 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novartis$1000
  • Pfizer$818
  • GSK$786
  • AbbVie$776
  • UCB, Inc.$735
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$8,52997%
  • Education$2523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,780 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$51,031
Medicare patients
57
Services billed
8,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept42$312,295
Humira(Cf) PenAdalimumab29$298,402
EnbrelEtanercept17$127,627
Duloxetine Hcl495$10,729
Hydroxychloroquine Sulfate186$9,374
MethotrexateMethotrexate Sodium254$8,480
Leflunomide115$6,217
Gabapentin251$4,142
Pilocarpine Hcl33$2,870
Azathioprine33$1,857
Methylprednisolone269$1,500
Pregabalin59$1,476
Colchicine20$1,294
Prednisone135$1,140
Febuxostat17$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$2,903$127,62717 claims
Scilex Pharmaceuticals Inc.Colchicine$15$1,29420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →